It is not great news when we read that the Statutory Health Insurance systems face financial difficulties. It is not great news when the press blames the pharmaceutical industry for it, says Gilbert Mertens, health care policy advisor – EU and International Institutions, and a former senior executive at Germany’s Merck KGaA. In his opinion, instead of coming up with cost containment measure after cost containment measure, it is time to push for structural change... "new thinking" is long overdue.
Patients want “care" when they suffer, not rational budget talk, says Dr Mertens. Is society ready to pay the price? Will society give priority to ethics and solidarity or deny patients even short period of life extension because of the growing importance of “economics of care”??
Not too long ago, the cost of medicines did not matter that much, and only the efficacy, safety and quality of the pharmaceuticals involved were the parameters any decision was based on.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze